Constellation Pharmaceuticals (NASDAQ:CNST) Downgraded to “Hold” at Zacks Investment Research
According to Zacks, “Constellation Pharmaceuticals, Inc. operates as a bio-pharmaceutical company. It discovers and develops molecule therapeutics for the treatment of cancer, inflammatory and immunologic disorders. The company’s lead product candidates consists of CPI-1205, which inhibits enhancer of zeste homolog 2 and CPI-0610, which inhibits bromodomain and extra terminal domain. Constellation Pharmaceuticals, Inc. is based in Cambridge, United States. “
CNST has been the topic of several other reports. ValuEngine raised Constellation Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, August 1st. HC Wainwright reaffirmed a buy rating and issued a $18.00 price target on shares of Constellation Pharmaceuticals in a research report on Wednesday, June 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $16.00.
Constellation Pharmaceuticals (NASDAQ:CNST) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.80) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.80). On average, equities research analysts expect that Constellation Pharmaceuticals will post -3.06 EPS for the current year.
Several large investors have recently made changes to their positions in the company. Northern Trust Corp raised its stake in shares of Constellation Pharmaceuticals by 12.4% in the 4th quarter. Northern Trust Corp now owns 51,008 shares of the company’s stock valued at $204,000 after acquiring an additional 5,624 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Constellation Pharmaceuticals by 16.9% in the 4th quarter. Geode Capital Management LLC now owns 13,735 shares of the company’s stock valued at $55,000 after acquiring an additional 1,987 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Constellation Pharmaceuticals by 4,092.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 3,312 shares of the company’s stock valued at $45,000 after acquiring an additional 3,233 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Constellation Pharmaceuticals in the 1st quarter valued at approximately $221,000. Finally, Wade G W & Inc. bought a new position in shares of Constellation Pharmaceuticals in the 1st quarter valued at approximately $166,000. 64.86% of the stock is currently owned by institutional investors.
Constellation Pharmaceuticals Company Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Featured Story: How to calculate the intrinsic value of a stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.